Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 27, 2012

View Archived Issues

New inhibitors of V600E-mutant B-raf presented

Chugai presents new highly potent and selective AXL inhibitor

Pozen discusses FDA meeting on integrated aspirin therapy NDA

Bristol-Myers Squibb halts development of candidate hepatitis drug

JAK inhibitor reduces signs and symptoms of arthritis in phase III trials

Novel PET tracer for tau imaging shows promise in vivo

Zyclara approved in Europe

Updated results from EMILIA study of trastuzumab emtansine

Novartis reports new mTOR/PI3K inhibitors

Collaborating organizations in France design new candidate drugs for parasitic diseases

Novel beta1-adrenoceptor ligands developed in U.K.

FDA issues refuse to file letter for Lemtrada sBLA

New everolimus formulation approved in Japan

Data reported from TRILOGY ACS trial of prasugrel

Abbott presents discovery of multiple HCV NS5B inhibitors

Seattle Genetics kicks off new study in renal cell carcinoma

Ten-gene molecular signature predicts response to cancer radiotherapy

Baxter to discontinue manufacturing Gammagard product

Plavix approved for STEMI in Japan

Lilly reports topline phase III results in Alzheimer's disease

NICE issues draft guidance on product for stroke

GSK and Theravance complete phase III COPD program

Strattera approved in Japan for adult ADHD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...